Literature DB >> 15357780

Willingness to pay for on-demand and prophylactic treatment for severe haemophilia in Sweden.

K Steen Carlsson1, S Höjgård, S Lethagen, A Lindgren, E Berntorp, B Lindgren.   

Abstract

The objective of the present paper was to provide an estimate of the benefits of on-demand and prophylaxis treatment strategies for severe haemophilia in monetary terms. Using the contingent-valuation method, which simulates a missing market by asking people about their willingness to pay (WTP), we asked a representative sample (n = 609) of the Swedish population if they would be willing to pay a specific amount (bid) so that patients with severe haemophilia could receive on-demand treatment and another bid for prophylactic treatment. Different respondents were offered different bids and the bid vector ranged from 71 Euro cents to EUR 130. The order of the bid questions was randomized so that half of the respondents were asked first about their WTP for on-demand treatment, and then about their WTP for prophylaxis, while the order was reversed for the other half of the respondents. The mean estimated WTP (year 2002) was EUR 39 (95% CI 31-47) for on-demand and EUR 65 (95% CI 55-73) for prophylaxis. Our sensitivity analysis showed that the ranking of the two treatment alternatives was robust in that the WTP was greater for prophylaxis in all possible subsets. The point estimates of WTP varied somewhat in subsets defined by individual characteristics, but confidence intervals always overlapped that of the main results. The WTP for on-demand and prophylaxis exceeded the calculated cost of treatment per taxpayer of providing on-demand and prophylactic treatment, respectively, based on our previous results.

Entities:  

Mesh:

Year:  2004        PMID: 15357780     DOI: 10.1111/j.1365-2516.2004.00954.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

Review 1.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

3.  Determinants of willingness to pay for health services: a systematic review of contingent valuation studies.

Authors:  Caroline Steigenberger; Magdalena Flatscher-Thoeni; Uwe Siebert; Andrea M Leiter
Journal:  Eur J Health Econ       Date:  2022-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.